| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.01 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.01 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.01 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.01 |